Theravance Biopharma buy marge
Zusammenfassung
Diese Einschätzung wurde am 15.01.18 mit einem Endkurs von 24,34 € beendet. Die BUY Einschätzung von marge schloss mit einer Rendite von -30,62 %. marge hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Theravance Biopharma | -11,24 % | -11,24 % | -25,74 % | -46,81 % |
iShares Core DAX® | -0,68 % | 1,89 % | 15,37 % | 17,16 % |
iShares Nasdaq 100 | 0,33 % | 4,63 % | 29,82 % | 56,19 % |
iShares Nikkei 225® | -1,49 % | -2,36 % | 7,67 % | 3,63 % |
iShares S&P 500 | -0,52 % | 2,32 % | 25,46 % | 46,45 % |
Kommentare von marge zu dieser Einschätzung
In der Diskussion Theravance Biopharma diskutieren
TBPH: Revefenacin for Chronic Obstructive Pulmonary disease [COPD]
Mid trial safety data for COPD treatment via Revefenacin is expected mid 2017. TBPH developed Revefenacin in conjunction with Mylan (MYL).
Phase 2 and Phase 2b studies demonstrated clinically significant improvements in lung function in COPD patients. COPD progressively makes it harder to breathe over time and induces coughing fits. The most common cause of COPD is smoking, and over 12 million Americans have the disease. The National Institute of Health [NIH] estimates 12 million more Americans may have undiagnosed COPD. 120,000 people die each year from the disease, and although there are currently treatments to address the symptoms, a best in class drug from TBPH would be a major boon for the company and for those stuck with COPD.
Regarding their other projects, TBPH has a large, diverse pipeline researching treatments for a swath of infectious diseases, respiratory issues, gastrointestinal problems, and cardiovascular concerns.